Edgewise Therapeutics
Developer of sarcomere modulators for hypertrophic cardiomyopathy and heart failure.
Something off on this page? Send us feedback.
Profile
Develops oral small-molecule sarcomere modulators for hypertrophic cardiomyopathy, heart failure and other cardiovascular or cardiometabolic diseases. Following the completed sale of its muscular dystrophy business, the pipeline centers on EDG-7500, EDG-15400 and EDG-003; no product is approved, so the business depends on clinical and regulatory progress.
Develops oral small-molecule therapies that modulate muscle sarcomere proteins, now concentrating on cardiovascular disease after completing the sale of sevasemten and its muscular dystrophy business to Servier. EDG-7500 is being studied in obstructive and non-obstructive hypertrophic cardiomyopathy, while EDG-15400 is being developed for heart failure with preserved ejection fraction. EDG-003 addresses an undisclosed cardiovascular or cardiometabolic target.
Combines muscle biology, small-molecule engineering and integrated muscle-function assays to discover and advance sarcomere modulators. Research and development are managed as one segment, with operations and fixed assets in the United States.
Has no approved products and generates no product revenue. Future operations depend on clinical-trial results, regulatory approvals, intellectual-property protection and third parties that manufacture drug candidates.
Company facts
Key statistics
Year to date +80.1% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Goldman Sachs | Reiterate | Neutral | $32 | $36 |
| Jul 20, 2026 | Evercore ISI | Reiterate | Outperform | $45 | $55 |
| Jul 9, 2026 | Oppenheimer | Initiate | Outperform | $51 | |
| Jul 6, 2026 | Guggenheim | Reiterate | Buy | $51 | |
| Jun 17, 2026 | RBC Capital | Reiterate | Outperform | $48 | $59 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.47 | −$0.53 | −13.3% | — | — | — | −1.27% |
| May 7, 2026Q1 FY26 | −$0.50 | −$0.46 | +8.0% | — | — | — | −0.73% |
| Feb 26, 2026Q4 FY25 | −$0.43 | −$0.47 | −9.3% | — | — | — | +2.63% |
| Nov 6, 2025Q3 FY25 | −$0.40 | −$0.39 | +2.5% | — | — | — | +0.41% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$590.0K | $0 | |
| Operating income | −$46.0M | −$42.6M | −$46.9M | −$56.0M | −$54.1M | −$61.9M | |
| Net income | −$40.8M | −$36.1M | −$40.7M | −$50.2M | −$49.0M | −$57.3M | |
| Diluted EPS | −$0.43 | −$0.34 | −$0.39 | −$0.47 | −$0.46 | −$0.53 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $460.7M · Total debt $3.6M · Total assets $479.7M · Shareholders' equity $448.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 107.59M · Float 79.59M · 74.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15.52M | 14.42% | 13F | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 10.22M | 9.49% | 13F | Aug 14, 2026 |
| Ra Capital Management, L.P. | 8.39M | 7.80% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 6.61M | 6.14% | 13F | Aug 7, 2026 |
| Jupiter Topco LLC | 6.08M | 5.65% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Kevin Koch | director, officer: President and CEO | −17,971 | $43.68 |
| Aug 12, 2026 | Behrad Derakhshan | officer: Chief Business Officer | −5,100 | $43.81 |
| Aug 12, 2026 | John R. Moore | officer: General Counsel | −5,016 | $43.82 |
| Aug 12, 2026 | Alan J. Russell | director, officer: Chief Scientific Officer | −5,901 | $43.73 |
| Aug 13, 2026 | Joanne M. Donovan | officer: CMO | −2,919 | $43.41 |
Peers
- Bristol-Myers Squibb
First approved cardiac myosin inhibitor for symptomatic obstructive HCM
- Cytokinetics
FDA-approved cardiac myosin inhibitor MYQORZO now commercial for oHCM
- Sarepta Therapeutics
Dominant DMD franchise via gene therapy, exon skipping, and RNA medicine
- Tenaya Therapeutics
AAV9 gene therapy targeting MYBPC3-mutant HCM and PKP2-mutant ARVC
- Capricor Therapeutics
Allogeneic cell therapy targeting DMD cardiomyopathy; BLA under FDA review
- Wave Life Sciences
Stereopure RNA oligonucleotide platform; NDA-stage exon-53 DMD program
- PTC Therapeutics
Rare-disease biopharma with DMD portfolio and PKU growth product Sephience
- Rocket Pharmaceuticals
AAV gene therapy for inherited cardiomyopathies: Danon, PKP2-ACM, BAG3-DCM
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics | $42.76 | −0.04% | $4.60B | — | — | — | — |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Cytokinetics | $72.50 | +0.54% | $8.97B | — | — | 126.4 | −57.1% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Tenaya Therapeutics | $0.6956 | +0.40% | $149.8M | — | — | 112.2 | — |
| Capricor Therapeutics | $9.64 | +0.41% | $551.5M | — | — | — | — |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| PTC Therapeutics | $70.59 | +0.73% | $5.85B | — | 58.0 | 5.8 | +101.6% |
| Rocket Pharmaceuticals | $3.82 | −0.91% | $421.5M | — | — | — | — |
| Median | 14.7 | 26.3 | 10.5 | −34.3% |